ALNY News and Press, Alnylam Pharmaceuticals Inc. From 05/18/22

Alnylam Pharmaceuticals (NASDAQ:ALNY) said Health Canada issued a notice of compliance (NOC) authorizing its Oxlumo (lumasiran) injection for subcutaneous use as a therapy for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adult patients. PH1 is a rare...

Alnylam Announces Health Canada Authorization of OXLUMO™ (lumasiran), the First and Only Treatment for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Paediatric and Adult Patients Canada NewsWire Authorization Based on two Pivotal Phase III tria...

BBH’s price multiples indicate an undervaluation and its major holdings have started recording significant price growth. BBH has strong fundamentals and has performed well enough in the medium and long term. BBH will face some minor ups and downs since most stocks are yet t...

Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2022 Earnings Conference Call April 28, 2022 08:30 AM ET Company Participants Christine Lindenboom - Senior Vice President of Investor Relations and Corporate Communications Yvonne Greenstreet - Chief Executive Officer Tolga Tanguler - Chief Commercial ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) stock has lost 9% to $140.98 in Thursday afternoon trade, after the company reported a miss on Q1 2022 earnings and cut guidance for 2022 combined net product revenues. ALNY posted Q1 non-GAAP EPS of -$1.49, which missed estimates by $0.03. Revenue of $21...

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Alnylam Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation

Alnylam Pharmaceuticals press release (NASDAQ:ALNY): Q1 Non-GAAP EPS of -$1.49 misses by $0.03. Revenue of $213.26M (+20.1% Y/Y) misses by $29.56M. Cash, cash equivalents and marketable securities were $2.24 billion as of March 31, 2022 compared to $2.44 billion as of December 31, 2021 with t...

− Achieved First Quarter 2022 Global Net Product Revenues of $187 Million for ONPATTRO ® , GIVLAARI ® , and OXLUMO ® – − Reported Positive 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in hATTR Amyloidosis Patients w...

HQL pays regular quarterly dividends with a close to double digit yield, and despite poor price growth over medium and long run, HQL’s total return is impressive. In the past three months, a dividend cut and extension of buyback period played a significant role in price movemen...

Alnylam Pharmaceuticals (NASDAQ:ALNY) is scheduled to announce Q1 earnings results on Thursday, April 28th, before market open. The consensus EPS Estimate is -$1.46 (+11.0% Y/Y) and the consensus Revenue Estimate is $242.82M (+36.7% Y/Y). Over the last 2 years, ALNY has beaten EPS estimates 0...